Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02132793 · ClinicalTrials.gov registry record · NA
Remote Exercise for Learning Anger and Excitation Management
A NA study, sponsored by VA Pacific Islands Health Care System.
- Completed
- Registry status
- NA
- Development phase
- 58
- Enrollment target
NCT02132793: Completed NA study, sponsored by VA Pacific Islands Health Care System.
NCT02132793 is a NA study that has completed, run by VA Pacific Islands Health Care System. The registered enrollment target is 58 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02132793, a NA study, has completed, sponsored by VA Pacific Islands Health Care System.
- COMPLETED
- Registry status
- NA
- Development phase
- 58 participants
- Enrollment target
Study Summary
The immediate objective of this project was to demonstrate the feasibility of Remote Exercises for Learning Anger and Excitation Management (RELAX). The application is a remote, technology- enabled, anger treatment and management system based on current evidence-based CBT interventions. The project's objective was to show that RELAX (1) enables the practice of anger management strategies remotely through mobile phone interfaces; (2) integrates with evidence-based treatments through the implementation of an existing CBT anger management course; (3) provides information, direction, and feedback through physiological sensors and signal analysis; and (4) supports communication and direction by the therapist through a web-based therapist interface.
Primary Outcome
The DAR-5 is a reliable and valid screening measure of common anger reactions. Its brevity is useful for rapidly assessing the presence of anger problems in different populations. The strength of the DAR-5 is that it employs a minimum number of items to measure the anger construct. Item content pertains to anger frequency, intensity, duration, interpersonal aggressiveness, and the extent to which anger interferes with interpersonal relationships.
Interventions
- BEHAVIORAL Anger Management Therapy
- BEHAVIORAL Anger Management Therapy & RELAX app
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2014-03 |
| Est. Completion | 2016-05 |
| Phase | NA |
What the finished NCT02132793 record still lists
NCT02132793 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 58 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 2 interventions - of which Anger Management Therapy is the first listed.
NCT02132793 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02132793 about?
NCT02132793 is a clinical study titled "Remote Exercise for Learning Anger and Excitation Management". The immediate objective of this project was to demonstrate the feasibility of Remote Exercises for Learning Anger and Excitation Management (RELAX). The application is a remote, technology- enabled, anger treatment and management system based on current evidence-based CBT interventions. The project'...
What is the current status of trial NCT02132793?
This trial is currently completed. It is a NA study. The enrollment target is 58 participants. The study started on 2014-03. Estimated completion is 2016-05.
What interventions are being tested in trial NCT02132793?
The interventions under investigation include: Anger Management Therapy (BEHAVIORAL), Anger Management Therapy & RELAX app (BEHAVIORAL).
Who is sponsoring clinical trial NCT02132793?
This trial is sponsored by VA Pacific Islands Health Care System, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02132793's enrollment target sits among peer trials
58 1256th of 2000 higher than 740 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03587844 · 58 participants · Phase 2
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
- NCT03630991 · 58 participants · Phase 1
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
- NCT03949855 · 58 participants · Phase 2
Belimumab With Rituximab for Primary Membranous Nephropathy
- NCT04069273 · 58 participants · Phase 2
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia